19:45 , Mar 31, 2017 |  BC Week In Review  |  Company News

Agalimmune, BioLineRx deal

BioLineRx acquired cancer company Agalimmune for $3 million in cash and $3 million in BioLineRx shares up front, plus undisclosed milestones. Agalimmune's lead compound AGI-134 is slated to begin clinical testing to treat solid tumors...
18:44 , Nov 4, 2016 |  BioCentury  |  Emerging Company Profile

Exploiting alpha-GAL

By coating tumor cells with a synthetic carbohydrate, Agalimmune Ltd. can enlist naturally circulating polyclonal antibodies to destroy primary solid tumor cells and stimulate an adaptive immune response against metastases. The newco’s Alphaject therapies are...
07:00 , Apr 4, 2016 |  BioCentury  |  Emerging Company Profile

Sugar-coated bugs

Centauri Therapeutics Ltd .'s alphamer technology recruits a population of pre-existing, endogenous polyclonal antibodies to kill antibiotic-resistant bacteria. Centauri acquired the technology from Altermune Technologies LLC , a company founded by PCR inventor Kary Mullis....
07:00 , May 28, 2015 |  BC Innovations  |  Product R&D

Altermune's Alphamers

Altermune Technologies LLC is taking immunotherapy back to its day job of fighting infections with a new technology that coats bacteria with a sugar, and recruits circulating antibodies against the sugar to find and destroy...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

Alpha-gal glycolipids: Phase I data

A Phase I trial in 9 patients with unresectable metastatic melanoma with >=1 resectable cutaneous, subcutaneous or palpable lymph node metastasis showed that 2 intratumoral injections of alpha-gal glycolipids given 4 weeks apart were well...
07:00 , Aug 9, 2010 |  BC Week In Review  |  Clinical News

Replagal agalsidase alfa regulatory update

Shire disclosed in its 2Q10 financial results that it withdrew a rolling BLA for Replagal agalsidase alfa to treat Fabry's disease. On a conference call, Shire said the prolonged shortage of Fabrazyme agalsidase beta from...
07:00 , Aug 9, 2010 |  BioCentury  |  Finance

Moving on

It is not often that the evolution of a biotech company follows the script, but Movetis N.V. (Euronext: MOVE) has done just that. Since being spun out from Johnson & Johnson (NYSE:JNJ) three-plus years ago,...
07:00 , Aug 9, 2010 |  BioCentury  |  Finance

Moving On

It is not often that the evolution of a biotech company follows the script, but Movetis N.V. (Euronext: MOVE) has done just that. Since being spun out from Johnson & Johnson (NYSE:JNJ) three-plus years ago,...
00:29 , Aug 5, 2010 |  BC Extra  |  Company News

Shire withdraws Replagal BLA

Shire plc (LSE:SHP; NASDAQ:SHPGY) disclosed in its 2Q10 financial results that it withdrew a rolling BLA for Replagal agalsidase alfa to treat Fabry's disease. On a conference call, Shire said the prolonged shortage of Fabrazyme...
07:00 , Mar 29, 2010 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 3/26 cls Cell Therapeutics Inc. (NASDAQ:CTIC; Milan:CTIC) Rodman Reni Benjamin Downgrade Market perform (from market outperform) -30% $0.64 Benjamin also removed his target after...